The 3′UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1
Tóm tắt
Pseudogenes are now known to regulate their protein-coding counterparts. Additionally, disturbances of 3′UTRs could increase the risk of cancer susceptibility by acting as modulators of gene expression. The aim of this study was to investigate the roles of the pseudogene CYP4Z2P-3′UTR and functional gene CYP4Z1-3′UTR in breast cancer angiogenesis process. The levels of CYP4Z2P- and CYP4Z1-3′UTR and miRNA of interests were measured in 22 cancerous tissues paired with non-cancerous samples by qRT-PCR. The effects of CYP4Z2P- and CYP4Z1-3′UTR were studied by overexpression and RNA interference approaches in vitro and ex vivo. Insights of the mechanism of competitive endogenous RNAs were gained from bioinformatic analysis, luciferase assays, and western blot. The positive CYP4Z2P/CYP4Z1 interaction and negative interaction between predicted miRNAs and CYP4Z2P or CYP4Z1 were identified via qRT-PCR assay and bivariate correlation analysis. CYP4Z2P- and CYP4Z1-3′UTR share several miRNA-binding sites, including miR-211, miR-125a-3p, miR-197, miR-1226, and miR-204. The CYP4Z2P- and CYP4Z1-3′UTRs arrest the interference caused by of these miRNAs, resulting in increased translation of CYP4Z1. Moreover, ectopic expression of the CYP4Z2P- and CYP4Z1-3′UTRs exhibit tumor angiogenesis-promoting properties in breast cancer collectively by inducing the phosphorylation of ERK1/2 and PI3K/Akt. Co-transfection with Dicer siRNA reversed the CYP4Z2P 3′UTR-mediated changes. Additionally, PI3K or ERK inhibitors reversed CYP4Z2P- and CYP4Z1-3′UTR-mediated changes in VEGF-A expression. Increased CYP4Z2P- and CYP4Z1-3′UTR expression promotes tumor angiogenesis in breast cancer partly via miRNA-dependent activation of PI3K/Akt and ERK1/2. The CYP4Z2P- and CYP4Z1-3′UTRs could thus be used as combinatorial miRNA inhibitors.
Tài liệu tham khảo
Perry MM, Tsitsiou E, Austin PJ, Lindsay MA, Gibeon DS, Adcock IM, Chung KF (2014) Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respir Res 15(1):58
Zovoilis A, Mungall AJ, Moore R, Varhol R, Chu A, Wong T, Marra M, Jones SJ (2014) The expression level of small non-coding RNAs derived from the first exon of protein-coding genes is predictive of cancer status. EMBO Rep 15(4):402–410
Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436(7051):740–744
Chen CH, Cheng CY, Chen YC, Sue YM, Liu CT, Cheng TH, Hsu YH, Chen TH (2014) MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One 9(6):e99802
Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L, Dong X (2014) miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells. J Cancer Res Clin Oncol 140(10):1661–1670
Ling S, Birnbaum Y, Nanhwan MK, Thomas B, Bajaj M, Ye Y (2013) MicroRNA-dependent cross-talk between VEGF and HIF1alpha in the diabetic retina. Cell Signal 25(12):2840–2847
Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F et al (2011) Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147(2):344–357
Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, Cheloufi S, Hodges E, Anger M, Sachidanandam R, Schultz RM et al (2008) Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 453(7194):534–538
Han YJ, Ma SF, Yourek G, Park YD, Garcia JGN (2011) A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J 25(7):2305–2312
Guo X, Tang Y (2011) OCT4 pseudogenes present in human leukemia cells. Clin Exp Med 12(4):207–216
Yang J, Li T, Gao C, Lv X, Liu K, Song H, Xing Y, Xi T (2014) FOXO1 3′UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett 588(17):3218–3224
Jia J, Yao P, Arif A, Fox PL (2013) Regulation and dysregulation of 3′UTR-mediated translational control. Curr Opin Genet Dev 23(1):29–34
Nakagawa Y, Minato M, Sumiyoshi K, Maeda A, Hara C, Murase Y, Nishida T, Kubota S, Takigawa M (2013) Regulation of CCN1 via the 3′-untranslated region. J Cell Commun Signal 7(3):207–217
Mercer TR, Wilhelm D, Dinger ME, Solda G, Korbie DJ, Glazov EA, Truong V, Schwenke M, Simons C, Matthaei KI et al (2011) Expression of distinct RNAs from 3′ untranslated regions. Nucleic Acids Res 39(6):2393–2403
Swart M, Dandara C (2014) Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance. Front Genet 5:167
Rutnam ZJ, Du WW, Yang W, Yang X, Yang BB (2014) The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs. Nat Commun 5:2914
Rieger MA (2004) Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 64(7):2357–2364
Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H, Wang C, Wang X, Yang G, Cai X et al (2012) Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol 264(1):73–83
Zheng L, Li X, Gu Y, Ma Y, Xi T (2014) Pseudogene CYP4Z2P 3′UTR promotes angiogenesis in breast cancer. Biochem Biophys Res Commun 453(3):545–551
Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK et al (2006) Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12(2):653–661
Nicosia RF, Ottinetti A (1990) Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63(1):115–122
Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K et al (2014) Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear cell renal cell carcinoma progression. Mol Cancer Ther 13(12):3086–3097
Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, Arra C, Pierantoni GM, Fusco A (2014) HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget 5(18):8341–8354
Li L, Wang D, Xue M, Mi X, Liang Y, Wang P (2014) 3′UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network. Sci Rep 4:5406
Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16(11):2043–2050
Brown BD, Naldini L (2009) Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 10(8):578–585
Mitrovich QM, Anderson P (2005) mRNA surveillance of expressed pseudogenes in C. elegans. Curr Biol 15(10):963–967
Denzler R, Agarwal V, Stefano J, Bartel DP, Stoffel M (2014) Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell 54(5):766–776
Figliuzzi M, Marinari E, De Martino A (2013) MicroRNAs as a selective channel of communication between competing RNAs: a steady-state theory. Biophys J 104(5):1203–1213
Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Leopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP (2013) Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci USA 110(18):7154–7159
Paplomata E, O’Regan R (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 6(4):154–166
Britschgi A, Radimerski T, Bentires-Alj M (2013) Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: which combination makes the whole greater than the sum of its parts? Drug Resist Updat 16(3–5):68–72
Fu J, Tian C, Xing M, Wang X, Guo H, Sun L, Sun L, Jiang Z, Zhang L (2014) KU004 induces G1 cell cycle arrest in human breast cancer SKBR-3 cells by modulating PI3K/Akt pathway. Biomed Pharmacother 68(5):625–630
Marchese FP, Huarte M (2014) Long non-coding RNAs and chromatin modifiers: their place in the epigenetic code. Epigenetics 9(1):21–26
Thum T, Fiedler J (2014) LINCing MALAT1 and angiogenesis. Circ Res 114(9):1366–1368
Vitiello M, Tuccoli A, Poliseno L (2014) Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol (Dordr)